240 related articles for article (PubMed ID: 27853650)
1. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.
McWilliams EM; Mele JM; Cheney C; Timmerman EA; Fiazuddin F; Strattan EJ; Mo X; Byrd JC; Muthusamy N; Awan FT
Oncoimmunology; 2016; 5(10):e1226720. PubMed ID: 27853650
[TBL] [Abstract][Full Text] [Related]
2. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors.
Della Chiesa M; Vitale M; Carlomagno S; Ferlazzo G; Moretta L; Moretta A
Eur J Immunol; 2003 Jun; 33(6):1657-66. PubMed ID: 12778484
[TBL] [Abstract][Full Text] [Related]
3. A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells.
Davis ZB; Cogswell A; Scott H; Mertsching A; Boucau J; Wambua D; Le Gall S; Planelles V; Campbell KS; Barker E
PLoS Pathog; 2016 Feb; 12(2):e1005421. PubMed ID: 26828202
[TBL] [Abstract][Full Text] [Related]
4. Enhancing Natural Killer and CD8
Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
[TBL] [Abstract][Full Text] [Related]
5. Increased frequency of human leukocyte antigen-E inhibitory receptor CD94/NKG2A-expressing peritoneal natural killer cells in patients with endometriosis.
Galandrini R; Porpora MG; Stoppacciaro A; Micucci F; Capuano C; Tassi I; Di Felice A; Benedetti-Panici P; Santoni A
Fertil Steril; 2008 May; 89(5 Suppl):1490-6. PubMed ID: 17706207
[TBL] [Abstract][Full Text] [Related]
6. HLA-G recognition by human natural killer cells. Involvement of CD94 both as inhibitory and as activating receptor complex.
Pende D; Sivori S; Accame L; Pareti L; Falco M; Geraghty D; Le Bouteiller P; Moretta L; Moretta A
Eur J Immunol; 1997 Aug; 27(8):1875-80. PubMed ID: 9295021
[TBL] [Abstract][Full Text] [Related]
7.
Mac Donald A; Guipouy D; Lemieux W; Harvey M; Bordeleau LJ; Guay D; Roméro H; Li Y; Dion R; Béland K; Haddad E
Front Immunol; 2023; 14():1231916. PubMed ID: 37675109
[TBL] [Abstract][Full Text] [Related]
8. Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells.
Brooks AG; Borrego F; Posch PE; Patamawenu A; Scorzelli CJ; Ulbrecht M; Weiss EH; Coligan JE
J Immunol; 1999 Jan; 162(1):305-13. PubMed ID: 9886400
[TBL] [Abstract][Full Text] [Related]
9. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.
Kamiya T; Seow SV; Wong D; Robinson M; Campana D
J Clin Invest; 2019 May; 129(5):2094-2106. PubMed ID: 30860984
[TBL] [Abstract][Full Text] [Related]
10. NKG2A Expression Is Not
Mahaweni NM; Ehlers FAI; Sarkar S; Janssen JWH; Tilanus MGJ; Bos GMJ; Wieten L
Front Immunol; 2018; 9():1415. PubMed ID: 29988376
[TBL] [Abstract][Full Text] [Related]
11. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.
Braud VM; Allan DS; O'Callaghan CA; Söderström K; D'Andrea A; Ogg GS; Lazetic S; Young NT; Bell JI; Phillips JH; Lanier LL; McMichael AJ
Nature; 1998 Feb; 391(6669):795-9. PubMed ID: 9486650
[TBL] [Abstract][Full Text] [Related]
12. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents.
Yaqinuddin A; Kashir J
Med Hypotheses; 2020 Apr; 140():109777. PubMed ID: 32344314
[TBL] [Abstract][Full Text] [Related]
13. Expression of p58.2 or CD94/NKG2A inhibitory receptors in an NK-like cell line, YTINDY, leads to HLA Class I-mediated inhibition of cytotoxicity in the p58.2- but not the CD94/NKG2A-expressing transfectant.
Lin Chua H; Brahmi Z
Cell Immunol; 2002 Sep; 219(1):57-70. PubMed ID: 12473268
[TBL] [Abstract][Full Text] [Related]
14. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
15. Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines.
Lee J; Keam B; Park HR; Park JE; Kim S; Kim M; Kim TM; Kim DW; Heo DS
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5705-5715. PubMed ID: 36547689
[TBL] [Abstract][Full Text] [Related]
16. Functional anti-CD94/NKG2A and anti-CD94/NKG2C autoantibodies in patients with systemic lupus erythematosus.
Hagberg N; Theorell J; Hjorton K; Spee P; Eloranta ML; Bryceson YT; Rönnblom L
Arthritis Rheumatol; 2015 Apr; 67(4):1000-11. PubMed ID: 25510434
[TBL] [Abstract][Full Text] [Related]
17. IL-12-dependent inducible expression of the CD94/NKG2A inhibitory receptor regulates CD94/NKG2C+ NK cell function.
Sáez-Borderías A; Romo N; Magri G; Gumá M; Angulo A; López-Botet M
J Immunol; 2009 Jan; 182(2):829-36. PubMed ID: 19124726
[TBL] [Abstract][Full Text] [Related]
18. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells.
Ruggeri L; Urbani E; André P; Mancusi A; Tosti A; Topini F; Bléry M; Animobono L; Romagné F; Wagtmann N; Velardi A
Haematologica; 2016 May; 101(5):626-33. PubMed ID: 26721894
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome
Wurzer H; Filali L; Hoffmann C; Krecke M; Biolato AM; Mastio J; De Wilde S; François JH; Largeot A; Berchem G; Paggetti J; Moussay E; Thomas C
Front Immunol; 2021; 12():619069. PubMed ID: 34108958
[TBL] [Abstract][Full Text] [Related]
20. High-Density of FcγRIIIA
Denis Musquer M; Jouand N; Pere M; Lamer JE; Bézieau S; Matysiak T; Faroux R; Caroli Bosc FX; Rousselet MC; Leclair F; Mosnier JF; Toquet C; Gervois N; Bossard C
Front Oncol; 2021; 11():684478. PubMed ID: 34211852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
